Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2013
- Price to Earnings (P/E) since 2013
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Total asset turnover | = | Revenues1 | ÷ | Total assets1 | |
---|---|---|---|---|---|
Dec 31, 2022 | = | ÷ | |||
Dec 31, 2021 | = | ÷ | |||
Dec 31, 2020 | = | ÷ | |||
Dec 31, 2019 | = | ÷ | |||
Dec 31, 2018 | = | ÷ | |||
Dec 31, 2017 | = | ÷ | |||
Dec 31, 2016 | = | ÷ | |||
Dec 31, 2015 | = | ÷ | |||
Dec 31, 2014 | = | ÷ | |||
Dec 31, 2013 | = | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$ in millions
The financial data reveals a consistent upward trajectory in revenues over the ten-year period, increasing from $5,100 million in 2013 to $14,410 million in 2022. This steady growth suggests expanding business operations and market demand.
Total assets experienced a notable shift, rising modestly from $3,067 million in 2013 to $3,926 million in 2015, then sharply increasing to $21,208 million in 2016. Following this significant jump, total assets maintained relatively stable levels between $22,549 million and $25,337 million through 2022. This abrupt increase in assets in 2016 may indicate a major acquisition, investment, or restructuring event.
The total asset turnover ratio, which measures revenue generated per unit of asset, shows a declining trend from 1.66 in 2013 to 0.32 in 2016, corresponding with the sharp rise in assets. After 2016, the ratio gradually improved, reaching 0.57 by 2022. This recovery suggests enhanced efficiency in utilizing assets to generate revenues post-2016, although the ratio remains below the high levels observed prior to the asset increase.
- Revenue Trend
- Consistent growth year-over-year with a more pronounced increase starting in 2016, culminating in nearly threefold revenue by 2022 compared to 2013.
- Total Assets
- Modest growth from 2013 to 2015, followed by a sharp jump in 2016 and stabilization around the $24 billion to $25 billion range thereafter.
- Total Asset Turnover
- Declined sharply in 2016 due to asset growth, then improved steadily but remained below initial levels, indicating gradual enhancement in asset utilization efficiency.
Overall, the data indicates that the company expanded significantly in asset base around 2016, which temporarily diluted asset efficiency but has since worked to improve revenue generation relative to assets while sustaining consistent revenue growth.
Comparison to Competitors
IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2022 | |||||||||||||
Dec 31, 2021 | |||||||||||||
Dec 31, 2020 | |||||||||||||
Dec 31, 2019 | |||||||||||||
Dec 31, 2018 | |||||||||||||
Dec 31, 2017 | |||||||||||||
Dec 31, 2016 | |||||||||||||
Dec 31, 2015 | |||||||||||||
Dec 31, 2014 | |||||||||||||
Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc. | Health Care | |
---|---|---|
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).